TBPH NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Theravance Biopharma Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 16.86 USD
-0.4% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -1.7% below the Trend Line and sits at 59.1% of its 52-week range. The latest completed week returned -0.4%, after a -4.4% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is inexpensive relative to peers. Options positioning is mixed with 32/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: earnings are due in 13d.

Setup score 48 out of 100
Latest Close 16.86 USD 24 Jul 2026
1W Return -0.4% latest completed week
4W Return -4.4% short-term follow-through
12W Return 0.4% quarterly tape
Trend Breadth 61.5% 32 of 52 weeks active
Volume Ratio 1.5x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
  • Next-week expectancy is positive at 60.14% based on similar historical setup states.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -0.4% Latest completed week; four-week move -4.4%. Indicator stack 34/57 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 60.14% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Mixed 32/100 conviction; expected move 13.0%. News sentiment 57/100 55 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -1.7% below the Trend Line and sits at 59.1% of its 52-week range. The latest completed week returned -0.4%, after a -4.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.5x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4012-week average 0.34

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.40Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -4.4% over four weeks, 0.4% over 12 weeks, and 52.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-0.4%
4W-4.4%
12W0.4%
26W-16.7%
52W52.9%
Active trend streak0 weeks
Active weeks in one year32
Trend breadth61.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.40Latest activity-pressure read.
Pressure change-0.2%Four-week change in activity pressure.
Leadership-5.46Latest relative-leadership reading.
RS change-74.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength99/100Blend of value, momentum, and quality. Underlying universe rank 2; rank 1 is best.
Value91/100Relative valuation strength. Underlying universe rank 10; rank 1 is best.
Quality100/100Profitability and accounting quality. Underlying universe rank 1; rank 1 is best.
Momentum87/100Medium-term price momentum. Underlying universe rank 14; rank 1 is best.
Growth87/100Revenue and earnings growth. Underlying universe rank 14; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework98/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
7.6x
Price divided by trailing earnings.
Price / sales
8.0x
Market value relative to trailing revenue.
EV / EBITDA
4.6x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
40.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
80.4%
Gross profit retained from each unit of revenue.
Operating margin
126.4%
Operating profit retained from revenue.
Free-cash-flow margin
244.9%
Free cash flow generated from revenue.
Return on invested capital
153.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
68.2%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
720.4%
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
1.0%
Net share repurchases relative to market value.
Shareholder yield
1.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

TBPH shows mixed options pressure with a 32/100 conviction score, put-call volume ratio of n/a, expected move of 13.0%, and Sharemaestro trend signal inactive.

Conviction32/100
Expected move13.0%
Put/call volume
Pressure-12
Speculation0
Volatility76
Trend agreement74
Open options detail
Insider activity11 / 9

11 acquisitions and 9 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment57/100

Weighted news tone is neutral across 55 relevant articles.

18 positive · 32 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move13.0%Nearest-chain priced movement where available.
52-week drawdown-19.8%Distance below the 52-week high.
13-week volatility2.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2610 weeks finished lower.
Best week+8.1%Week of 6 Feb.
Worst week-25.6%Week of 6 Mar.
Latest week-0.4%Week of 24 Jul.

Shape of recent returns

Strong gains5
Modest gains9
Flat weeks2
Modest losses4
Sharp losses6
Recent vol2.7%13-week weekly-return volatility.
Base vol6.1%52-week weekly-return volatility.
Up/down split33/17Count of positive and negative weeks in the 52-week window.
Average skew4.1% / -4.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape48/100

Trend, activity pressure, participation, and risk combine to a 48/100 tape read.

 Indicator analysis26/100

Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 0/12.

Activity pressure 0.40; No reversal markers Next-Week ExpectancyPositive 60.14%

Next-week expectancy is positive with a 60.14% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors94/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 30; Small Cap Core rank 29 SVQF98/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 12.5 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options52/100

TBPH shows mixed options pressure with a 32/100 conviction score, put-call volume ratio of n/a, expected move of 13.0%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 13.0% Sentiment57/100

Weighted news tone is neutral across 55 relevant articles.

Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks Insiders11 / 9

11 acquisitions and 9 disposals in the latest 180-day insider tape.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202616.86 USD-0.4%17.15 USD11.71 USD0.40-5.464.1MOff
17 Jul 202616.93 USD0.0%17.21 USD11.67 USD0.60-6.232.7MOff
10 Jul 202616.93 USD0.0%17.27 USD11.62 USD0.65-9.853.3MOff
3 Jul 202616.93 USD-4.0%17.31 USD11.57 USD0.61-8.028.1MOff
26 Jun 202617.63 USD6.3%17.37 USD11.53 USD0.40-3.134.2MOff
19 Jun 202616.58 USD-0.4%17.46 USD11.48 USD0.04-12.712.1MOff
12 Jun 202616.64 USD2.1%17.52 USD11.45 USD-0.17-9.911.4MOff
5 Jun 202616.29 USD1.4%17.55 USD11.41 USD-0.39-9.592.2MOff
29 May 202616.06 USD-1.9%17.49 USD11.37 USD-0.49-14.761.6MOff
22 May 202616.37 USD0.9%17.45 USD11.34 USD-0.58-10.331.7MOff
15 May 202616.22 USD-4.6%17.38 USD11.31 USD-0.68-9.772.0MOff
8 May 202617.01 USD1.3%17.31 USD11.27 USD-0.69-5.311.4MOff
1 May 202616.79 USD2.0%17.21 USD11.24 USD-0.80-0.981.4MOff
24 Apr 202616.46 USD-4.5%17.13 USD11.20 USD-0.87-1.152.0MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.